Again? Go back and restate what has been discussed here over many months about the internal state of the CNS pharma industry? For someone who cites Pfizer's share price, and valuation changes for a handful of small companies who have had NDAs filed or approved, as somehow being relevant to the partnering environment for Cortex?
It would be like trying to have a coherent discussion with Glenn Beck about health care reform. Not worth the expended oxygen.
Market Data 
Markets 
AI
